Guggenheim Maintains Buy on Johnson & Johnson, Raises Price Target to $287

Benzinga · 2d ago
Guggenheim analyst Vamil Divan maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $270 to $287.